Equities research analysts expect SomaLogic, Inc. (NASDAQ:SLGC – Get Rating) to report $23.30 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for SomaLogic’s earnings. The lowest sales estimate is $23.00 million and the highest is $23.60 million. The business is scheduled to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that SomaLogic will report full-year sales of $106.20 million for the current financial year, with estimates ranging from $105.00 million to $107.40 million. For the next year, analysts expect that the company will report sales of $150.80 million, with estimates ranging from $145.00 million to $156.60 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow SomaLogic.
SomaLogic (NASDAQ:SLGC – Get Rating) last announced its quarterly earnings results on Tuesday, March 29th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01).
Several equities research analysts have recently weighed in on the company. Stifel Nicolaus assumed coverage on SomaLogic in a research note on Tuesday, February 1st. They issued a “buy” rating and a $12.00 price objective on the stock. Jefferies Financial Group began coverage on SomaLogic in a research report on Friday, December 10th. They set a “buy” rating and a $16.00 price target on the stock. Zacks Investment Research lowered SomaLogic from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, began coverage on SomaLogic in a research report on Tuesday, December 14th. They set a “buy” rating and a $19.00 price target on the stock. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $16.25.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. bought a new position in SomaLogic during the 3rd quarter worth about $37,000. Wolverine Asset Management LLC acquired a new stake in SomaLogic in the 4th quarter valued at about $36,000. UBS Group AG acquired a new stake in SomaLogic in the 3rd quarter valued at about $58,000. Penserra Capital Management LLC acquired a new stake in SomaLogic during the fourth quarter worth approximately $98,000. Finally, Citadel Advisors LLC acquired a new stake in SomaLogic during the third quarter worth approximately $129,000. Institutional investors and hedge funds own 44.55% of the company’s stock.
Shares of SLGC opened at $7.79 on Wednesday. SomaLogic has a 12-month low of $7.02 and a 12-month high of $14.72. The stock’s 50-day moving average price is $8.53 and its 200 day moving average price is $10.48.
About SomaLogic
SomaLogic, Inc operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples.